Portland, OR, July 02, 2019 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others], Infection Type [Superficial Antifungal Infection and Systemic Antifungal Infection], Dosage form [Drugs, Ointment, Powder, and Others] and Therapeutic Indication [Aspergillosis, Dermatophytosis, Candidiasis, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023”.
Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/2370
According to the report, the global Antifungal Drugs market generated $14.23 billion in 2017 and is estimated to reach $17.72 billion by 2023, growing at a CAGR of 3.7% from 2017 to 2023. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario.
Favorable government funds to combat the antifungal diseases along with the increasing prevalence of fungal infection drive the growth of the market. Furthermore, rising awareness levels pertaining to myriad fungal infections supplement the market growth. However, the growing population with antifungal drug resistance and the presence of counterfeit drugs and side effects of antifungal drugs restrict the growth. On the other hand, patent expirations and increasing funding from public & private organizations offer lucrative opportunities for the market.
Based on drug types, the Azoles segment accounted for nearly two-fifths of the total market share in 2017 and is expected to maintain its dominance by 2023. Furthermore, this segment is estimated to project the fastest CAGR of 4.1% from 2017 to 2023.
Based on dosage form, the drugs segment held nearly one-third of the total market share in 2017 and will maintain its dominance throughout the forecast period. Furthermore, this segment is estimated to register the highest growth rate with a CAGR of 4.2% from 2017 to 2023.
Based on the region, Asia-Pacific would grow at the fastest CAGR of 4.5% from 2017 to 2023. However, the North America region contributed more than one-third of the total share in 2017 and is estimated to maintain its dominance during the forecast period. The report also includes the study of different regions such as Europe and LAMEA.
Based on therapeutic indication, Candidiasis segment held more than one-third of the total market share in 2017 and will maintain its dominance throughout the forecast period. However, the Dermatophytosis segment is estimated to register the highest growth rate with a CAGR of 4.1% from 2017 to 2023.
Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2370
The leading market players analyzed in the research include the GlaxoSmithKline Plc. Pfizer Inc., Enzon Pharmaceuticals, Inc., Sanofi S.A., Scynexis Inc., Gilead Sciences, Inc., Bayer AG, Merck & Co., Inc., Abbott Laboratories, and Novartis International AG. They have adopted different strategies such as mergers & acquisitions, partnerships, collaborations, new product launches, and others to gain a strong position in the global industry.
About Us:
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.